Pan-Nox inhibitor treatment improves renal function in aging murine diabetic kidneys.

IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY
Kidney Research and Clinical Practice Pub Date : 2024-11-01 Epub Date: 2023-08-10 DOI:10.23876/j.krcp.23.004
Jeong Hoon Park, Sung Gi Yoon, Jung Yeon Ghee, Ji Ae Yoo, Jin Joo Cha, Young Sun Kang, Sang Youb Han, Yun Jae Seol, Jee Young Han, Dae Ryong Cha
{"title":"Pan-Nox inhibitor treatment improves renal function in aging murine diabetic kidneys.","authors":"Jeong Hoon Park, Sung Gi Yoon, Jung Yeon Ghee, Ji Ae Yoo, Jin Joo Cha, Young Sun Kang, Sang Youb Han, Yun Jae Seol, Jee Young Han, Dae Ryong Cha","doi":"10.23876/j.krcp.23.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Aging is a risk factor for development of chronic kidney disease and diabetes mellitus with commonly shared features of chronic inflammation and increased oxidative stress. Here, we investigated the effect of pan-Nox-inhibitor, APX-115, on renal function in aging diabetic mice.</p><p><strong>Methods: </strong>Diabetes was induced by intraperitoneal injection of streptozotocin at 50 mg/kg/day for 5 days in 52-week-old C57BL/6J mice. APX-115 was administered by oral gavage at a dose of 60 mg/kg/day for 12 weeks in nondiabetic and diabetic aging mice.</p><p><strong>Results: </strong>APX-115 significantly improved insulin resistance in diabetic aging mice. Urinary level of 8-isoprostane was significantly increased in diabetic aging mice than nondiabetic aging mice, and APX-115 treatment reduced 8-isoprostane level. Urinary albumin and nephrin excretion were significantly higher in diabetic aging mice than nondiabetic aging mice. Although APX-115 did not significantly decrease albuminuria, APX-115 markedly improved mesangial expansion, macrophage infiltration, and expression of fibrosis molecules such as transforming growth factor beta 1 and plasminogen activator inhibitor 1. Interestingly, the expression of all Nox isoforms including Nox1, Nox2, and Nox4 was significantly increased in diabetic aging kidneys, and APX-115 treatment decreased Nox1, Nox2, and Nox4 protein expression in the kidney. Furthermore, Klotho expression was significantly decreased in diabetic aging kidneys, and APX-115 restored Klotho level.</p><p><strong>Conclusion: </strong>Our results provide evidence that pan-Nox inhibition may improve systemic insulin resistance and decrease oxidative stress, inflammation, and fibrosis in aging diabetic status and may have potential protective effects on aging diabetic kidney.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"763-773"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11615449/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Research and Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23876/j.krcp.23.004","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Aging is a risk factor for development of chronic kidney disease and diabetes mellitus with commonly shared features of chronic inflammation and increased oxidative stress. Here, we investigated the effect of pan-Nox-inhibitor, APX-115, on renal function in aging diabetic mice.

Methods: Diabetes was induced by intraperitoneal injection of streptozotocin at 50 mg/kg/day for 5 days in 52-week-old C57BL/6J mice. APX-115 was administered by oral gavage at a dose of 60 mg/kg/day for 12 weeks in nondiabetic and diabetic aging mice.

Results: APX-115 significantly improved insulin resistance in diabetic aging mice. Urinary level of 8-isoprostane was significantly increased in diabetic aging mice than nondiabetic aging mice, and APX-115 treatment reduced 8-isoprostane level. Urinary albumin and nephrin excretion were significantly higher in diabetic aging mice than nondiabetic aging mice. Although APX-115 did not significantly decrease albuminuria, APX-115 markedly improved mesangial expansion, macrophage infiltration, and expression of fibrosis molecules such as transforming growth factor beta 1 and plasminogen activator inhibitor 1. Interestingly, the expression of all Nox isoforms including Nox1, Nox2, and Nox4 was significantly increased in diabetic aging kidneys, and APX-115 treatment decreased Nox1, Nox2, and Nox4 protein expression in the kidney. Furthermore, Klotho expression was significantly decreased in diabetic aging kidneys, and APX-115 restored Klotho level.

Conclusion: Our results provide evidence that pan-Nox inhibition may improve systemic insulin resistance and decrease oxidative stress, inflammation, and fibrosis in aging diabetic status and may have potential protective effects on aging diabetic kidney.

泛氮氧化物抑制剂治疗可改善衰老小鼠糖尿病肾脏的肾功能。
背景:衰老是慢性肾脏疾病和糖尿病发展的危险因素,其共同特征是慢性炎症和氧化应激增加。本实验研究了泛一氧化氮抑制剂APX-115对衰老型糖尿病小鼠肾功能的影响。方法:52周龄C57BL/6J小鼠腹腔注射链脲佐菌素50 mg/kg/d,连续5 d诱导糖尿病。APX-115以60 mg/kg/天的剂量灌胃给药于非糖尿病和糖尿病衰老小鼠,连续12周。结果:APX-115显著改善糖尿病老龄小鼠的胰岛素抵抗。糖尿病老龄小鼠尿中8-异前列腺素水平明显高于非糖尿病老龄小鼠,APX-115治疗可降低8-异前列腺素水平。糖尿病老龄小鼠尿白蛋白和肾素排泄量明显高于非糖尿病老龄小鼠。虽然APX-115没有显著降低蛋白尿,但APX-115明显改善了系膜扩张、巨噬细胞浸润和纤维化分子如转化生长因子β 1和纤溶酶原激活物抑制剂1的表达。有趣的是,包括Nox1、Nox2和Nox4在内的所有Nox异构体在糖尿病衰老肾脏中的表达均显著增加,APX-115治疗降低了肾脏中Nox1、Nox2和Nox4蛋白的表达。此外,糖尿病老化肾脏中Klotho表达明显降低,APX-115恢复了Klotho水平。结论:pan-Nox抑制可改善糖尿病患者的全身胰岛素抵抗,减少氧化应激、炎症和纤维化,并可能对糖尿病肾脏衰老具有潜在的保护作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.60
自引率
10.00%
发文量
77
审稿时长
10 weeks
期刊介绍: Kidney Research and Clinical Practice (formerly The Korean Journal of Nephrology; ISSN 1975-9460, launched in 1982), the official journal of the Korean Society of Nephrology, is an international, peer-reviewed journal published in English. Its ISO abbreviation is Kidney Res Clin Pract. To provide an efficient venue for dissemination of knowledge and discussion of topics related to basic renal science and clinical practice, the journal offers open access (free submission and free access) and considers articles on all aspects of clinical nephrology and hypertension as well as related molecular genetics, anatomy, pathology, physiology, pharmacology, and immunology. In particular, the journal focuses on translational renal research that helps bridging laboratory discovery with the diagnosis and treatment of human kidney disease. Topics covered include basic science with possible clinical applicability and papers on the pathophysiological basis of disease processes of the kidney. Original researches from areas of intervention nephrology or dialysis access are also welcomed. Major article types considered for publication include original research and reviews on current topics of interest. Accepted manuscripts are granted free online open-access immediately after publication, which permits its users to read, download, copy, distribute, print, search, or link to the full texts of its articles to facilitate access to a broad readership. Circulation number of print copies is 1,600.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信